MedPlus Health Services promoters declare no new share encumbrances in Q4FY26

MedPlus Health Services Limited disclosed on April 07, 2026, that its promoters have not created any new encumbrances on their shareholdings during the quarter ended March 31, 2026. The declarations were submitted in compliance with Regulation 31(4) of the SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. This disclosure assures investors that the promoter group's shareholding remains free from additional charges or pledges beyond those previously reported in the financial year.

The declarations were received from three key promoter entities: Gangadi Madhukar Reddy, Agilemed Investments Private Limited, and Lone Furrow Investments Private Limited. Each entity confirmed that no direct or indirect encumbrances were established on the shares held by them during the specified period. The only encumbrances in effect are those that had already been disclosed to the exchanges during the Financial Year 2025-26.

Promoter Declarations

The following table details the promoters who submitted the declarations for the period ended March 31, 2026:

Promoter Name	Status
Gangadi Madhukar Reddy	No new encumbrances
Agilemed Investments Private Limited	No new encumbrances
Lone Furrow Investments Private Limited	No new encumbrances

The confirmations were addressed to the Audit Committee of MedPlus Health Services Limited and subsequently forwarded to BSE Limited and National Stock Exchange of India Limited. Manoj Kumar Srivastava, Company Secretary & Compliance Officer, filed the intimation on behalf of the company.

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
-0.53%	+1.47%	+2.67%	+11.82%	-5.48%	-20.14%

MedPlus Health Services has disclosed that its subsidiary, Optival Health Solutions Private Limited, has received two additional suspension orders for drug licenses at stores in Telangana. This follows previous regulatory actions reported in Maharashtra, Telangana, Karnataka, and Delhi. The latest updates, dated May 30, 2026, involve suspensions for stores in Nalgonda and Serilingampali. The disclosures were made pursuant to Regulation 30 read with Para A Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Drug License Suspension Details

The regulatory actions now span seventeen separate stores across five states, each involving a suspension of the drug license under Rule 65 of the Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945. The following table summarises the key details of all regulatory actions as disclosed by the company:

Parameter:	Store 1	Store 2	Store 3	Store 4	Store 5	Store 6	Store 7	Store 8	Store 9	Store 10	Store 11	Store 12	Store 13	Store 14	Store 15	Store 16	Store 17
Authority:	Asst. Commissioner & Licensing Authority, FDA, MH, Nashik	Assistant Director, DCA, Nizamabad, Telangana	Assistant Director, DCA, Bidar Circle, Karnataka	Assistant Director, DCA, F-17, Karkardooma, Delhi	Assistant Director, DCA, Bangalore circle-2, Karnataka	Assistant Director, DCA, Chikkamagalur Circle, Karnataka	Assistant Director, DCA, Hospet Circle, Vijaynagar, Karnataka	Assistant Director, Drugs Control Administration, Shameerpet, Telangana	Assistant Director, Drugs Control Administration, Siddipet, Telangana	Assistant Director, Drugs Control Administration, Shimoga Circle, Karnataka	Assistant Director, Drugs Control Administration, Madikeri Circle, Karnataka	Assistant Director, Drugs Control Administration, Bangalore Circle-4, Karnataka	Assistant Director, Drugs Control Administration, Shameerpet-Mechel-Malkajgiri Dist, Telangana	Assistant Director, Drugs Control Administration Bangalore Rural Circle, Devanahalli, Karnataka	Assistant Director, Drugs Control Administration Bangalore circle-5, Bangalore, Karnataka	Assistant Director, Drugs Control Administration, Nalgonda, Telangana	Assistant Director, Drugs Control Administration, Serilingampali, Telangana
Nature of Action:	Suspension for five days	Suspension for one day	Suspension for one day	Suspension for one day	Suspension for three days	Suspension for two days	Suspension for two days	Suspension for three days	Suspension for two days	Suspension for five days	Suspension for two days	Suspension for three days	Suspension for three days	Suspension for two days	Suspension for one day	Suspension for five days	Suspension for two days
Store Location:	Samta Nagar, Nashik, Maharashtra	Metpally Road Armoor, Telangana	Shivnagar Bidar, Karnataka	Gopal Nagar, New Delhi	Kalidasa Layout, Karnataka	Mg Road Chikkamagaluru, Karnataka	Basaveshwara Nagar, Karnataka	Mallapur, Telangana	Market Road Narsapur, Telangana	Vinobha Nagar, Karnataka	Kohinoor Road, Madikeri, Karnataka	Nagarabhavi 2nd Stage, Karnataka	Maruthi Nagar Kothapet Village, Telangana	Channappa Layout Nelamangala, Karnataka	Binny Mill Road Ganganagar, Karnataka	Nareducharla Main Road, Telangana	Laxmi Nagar Colony Hydershahkote Exp, Telangana
Date of Receipt of Order:	May 06, 2026	May 08, 2026	Not specified	May 10, 2026	May 11, 2026	Not specified	May 12, 2026	May 15, 2026	May 20, 2026	Not specified	May 22, 2026	Not specified	May 27, 2026	Not specified	Not specified	May 30, 2026	Not specified
Violation:	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Not specified	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Rules, 1945	Not specified	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945	Under Rule 65 of Drugs and Cosmetics Act, 1940 and Drugs and Cosmetics Rules, 1945
Potential Revenue Loss:	Rs 0.75 lacs	Rs 0.09 lacs	Rs 0.15 lacs	Rs 0.30 lacs	Rs 0.64 lacs	Rs 2.07 lacs	Rs 0.76 lacs	Rs 2.49 lacs	Rs 0.18 lacs	Rs 4.85 lacs	Rs 0.54 lacs	Rs 1.98 lacs	Rs 1.35 lacs	Rs 1.49 lacs	Rs 0.65 lacs	Rs 0.85 lacs	Rs 0.18 lacs

Regulatory and Financial Impact

The latest updates include a five-day suspension for a store at Nareducharla Main Road, Telangana, and a two-day suspension for a store at Laxmi Nagar Colony Hydershahkote Exp, Telangana. These actions result in a potential revenue loss of Rs 0.85 lacs and Rs 0.18 lacs, respectively. The total potential revenue loss across all reported suspensions now amounts to Rs 20.17 lacs.

The disclosures were made by Gangadi Madhukar Reddy, Managing Director and Chief Executive Officer of MedPlus Health Services. The details of these regulatory actions are available on the company's website at www.medplusindia.com , as well as on the websites of BSE Limited and the National Stock Exchange of India Limited.